Naiwanel (Drospirenone, Ethinylestradiol)

Drospirenone/Ethinylestradiol, the active ingredient in Naiwanel, is a combined oral contraceptive presented as an oral tablet for oral use. It prevents pregnancy and helps regulate menstrual cycles in women of reproductive age. It combines a progestogenic component with an estrogenic component to provide effective contraception while offering benefits such as reduced water retention and a favorable effect on acne.

GNH USA supplies Naiwanel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with European Union marketing authorisation standards and is distributed under Good Distribution Practice, ensuring quality and traceability for healthcare providers worldwide.

Naiwanel, a combined oral contraceptive, acts on the hormonal regulation pathway to prevent pregnancy and manage menstrual health.

Prevention of pregnancy: provides reliable contraceptive protection for women of reproductive age. Regulation of menstrual cycles: helps achieve more predictable bleeding patterns and reduces cycle irregularities. Management of menstrual‑related symptoms: can lessen dysmenorrhea and premenstrual mood changes associated with hormonal fluctuations.

Naiwanel may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Nausea: mild stomach upset, especially during the first cycles. - Breast tenderness: temporary swelling or discomfort of the breasts. - Headache: mild to moderate head pain that may resolve with continued use. - Spotting between periods: light vaginal bleeding or spotting.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins, potentially leading to pulmonary embolism. - Severe liver disorders: jaundice, hepatic dysfunction, or hepatic adenoma. - Anaphylaxis: life‑threatening allergic reaction with hives, swelling, or breathing difficulty.

Before prescribing Naiwanel, clinicians should evaluate patient risk factors and provide appropriate counseling. - Assess cardiovascular risk: review history of thrombosis, hypertension, or smoking. - Avoid smoking: especially in women over 35 years of age due to increased clot risk. - Monitor blood pressure: check regularly during treatment. - Review concomitant medications: consider potential drug interactions that may affect efficacy. - Store at ambient temperature: keep in the original packaging, protect from moisture and light.

Naiwanel can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce contraceptive efficacy. - Additional estrogen‑containing products (e.g., hormone replacement therapy): increase risk of thromboembolic events.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., ketoconazole): can increase hormone plasma levels, potentially enhancing side effects. - Selective serotonin reuptake inhibitors (SSRIs): may increase bleeding tendency. - St. John’s wort: may lower hormone concentrations, reducing contraceptive reliability.